Rhythm Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 87 to 91 Friday.
IBD's proprietary RS Rating measures market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners typically have an RS Rating of above 80 at the beginning of a new price run.
Looking For The Best Stocks To Buy And Watch? Start Here
The IBD 50 stock is trying to complete a double bottom with a 63.44 buy point. See if it can clear the breakout price in volume at least 40% above average.
The company posted 0% EPS growth in its most recent report. Sales gains came in at 48%.
Rhythm Pharmaceuticals earns the No. 50 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Neurocrine Biosciences are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
